Serpin has demonstrated promising pre-clinical results in several additional disease models. While currently focusing its development on AMI, the company has identified many other future opportunities in a wide array of inflammatory diseases. Given the mechanism of the peptide through blockade of specific innate immune responses and initiation of signaling receptors, there is potential for expanding the use of SP16 (and related analogues) to other pro-inflammatory and autoimmune diseases.

The market potential for these indications is immense. Serpin plans to move these programs to the clinical stage pending additional grants (three grants from NIH and VA state have already been awarded to Serpin-Pharma for the diabetes programs), others are scheduled for collaboration with partners. Six patents (some approved under review) protect the entire pipeline. The patent portfolio covers the “composition of matter”, as well as “use” of proprietary peptides derived from AAT and other serpins.

Lead Indication - SP16 and AMI

Acute myocardial infarction (AMI, or heart attack) remains a major cause of morbidity and mortality in the world, with roughly 500,000 new cases per year in the U.S. alone. Despite current strategies for early reperfusion (injecting oxygen to the heart), some patients die soon after AMI and those who do survive are at risk of heart failure and not necessarily healthy when they leave the hospital. There is a strong correlation between the severity of AMI and the incidence of other chronic cardiac diseases.

Learn More